MD Biosciences Blog

MD Biosciences Releases NeuroFreeze | Preserve Primary Neurons

Posted by MD Biosciences on Apr 7, 2015 8:47:00 PM

Zurich, Switzerland, April 1, 2015 – MD Biosciences, a global biotechnology company focused in neuroscience research, announces the launch of its new NeuroFreeze media for the freezing and culturing of rat and mouse hippocamal or cortex neurons. The proprietary freezing medium retains high viability, between 75-90%, and maintains all the expected characteristics of primary neurons in culture. 

Primary neurons from mice are a good model system to examine the structure and function of neurons and have been widely used very successfully by the neuroscience community. However, they are cumbersome to culture, need to be cultured directly from mice or rats and any excessive neurons that cannot be used need to be discarded leading to loss of precious tissue and unnecessary animal sacrifice. We have developed a proprietary freezing medium that allows these neurons to be frozen and cultured as required, an advantage to institutions striving to adhere to the principals of the 3Rs with emphasis on minimizing animal use for the only purpose of harvesting neurons.

preservedneurons 

Benefits of NeuroFreeze Freezing Medium:

  • Retain 75-90% viability of neurons
  • Maintain all expected characteristics of primary neurons, including morphology and expression of neuronal and synaptic markers
  • Eliminates lengthy stepwise termperature reduction protocols as with other preserving medium 

 

The use of NeuroFreeze media offers the convenience of thawing and using neurons as need arises without having to dissect an animal for neuron culture each time experiments need to be conducted. This would allow researchers to freeze neurons from control or diseased mice and culture them as necessary, a great advantage for researchers using mouse models of disease, or genetically engineered strains.

 

About MD Biosciences

MD Biosciences offers products for use in the inflammations, neurology, endocrinology, and metabolic disorders research fields. At MD Biosciences, we partner with the pharmaceutical, biotech, academic and government communities to provide the products needed with a client-focused approach. Our goal is to assist you in optimizing your own research process and reaching your objectives faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

 

Read More

Topics: Research Products, Neuropathy

MD Biosciences Launches New Products Division - MD Bioproducts

Posted by MD Biosciences on Oct 6, 2009 10:45:00 AM

MD Biosciences (MDB)  launches MD  Bioproducts, a division of MD Biosciences, in a continued effort to  meet client needs for high quality research products. The new division allows MD Biosciences to strengthen and expand it's product offering for immunology and cell biology research while maintaining its contract research focus within inflammation and neurology disease research.

While MD Biosciences has offered its products for purchase since 1991, the new division permits for increased product distribution by 140 percent. Cell Culture Related Reagents, Assays, Antibodies, Proteins, and Western Blot kits are some of the products MD Bioproducts currently provides. Currently, new products and product technologies are being explored and will be added to the development and manufacturing for the coming year.

"At MD Biosciences, our top priority has always been meeting the needs of our clients through the products we offer and customer experience we deliver. The launch of MD Bioproducts is a great step of convenience for our clients-accommodating them to optimize their research process. We know that our products offer accuracy and reproducibility so our clients can be confident in their results. Our quality reagents contribute to the success of our clients' research," stated MD Biosciences President, Eddie Moradian.

Apart from the key benefit of increased manufacturing opportunities, the new division provides a better resource for product purchasers. VP of Marketing & Sales, Amy Clausen said, "MD Bioproducts showcases a new, clean look--including packaging, logo and its own website, which allows for easy navigation and viewing of product features. We are thrilled to be taking this direction at MDB as it will simplify and improve the customer experience for the client." MD Bioproducts website may be visited at www.mdbioproducts.com.


About MD Biosciences

MD Biosciences provides contract research services including efficacy testing, mode of action platforms, in vitro analysis, and histology for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel. We provide a ready team of experts to tackle problems and provide solutions.

About MD Bioproducts

MD Bioproducts is a division of MD Biosciences offering high-quality reagents for immunology and cell biology research. Our goal is to provide products that are easy-to-use, accurate and reproducible – ultimately contributing to our client's research success.

###



The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Read More

Topics: Research Products

New Mouse anti-Collagen Type II (anti-CII) ELISAs.

Posted by Amy Clausen on Mar 3, 2008 11:27:00 AM


St Paul, MN March 4, 2008 – MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new line of Mouse anti-Collagen Type II (anti-mouse CII) ELISAs. The new Mouse anti-collagen CII ELISAs allow you to measure antibodies generated against the species of collagen used in the induction of arthritis in mice (bovine, human, mouse, rat, chicken, porcine). IgG and two subclasses (IgG2a and IgG2b) are now available as ready-to-use ELISAs that provide fast, accurate and reliable results.

 

The Collagen-induced arthritis (CIA) model is one of the most widely used models for the study of RA. Collagen type II (CII) in adjuvant is used to induce arthritis by triggering autoreactive B cells, which play an important role in the development of arthritis. This B cell response to CII is strictly T cell dependent, where the B cells predominantly switch isotype to IgG.

 

The anti-Type II Collagen ELISAs offer many improvements over other commercially available anti-Collagen Type II ELISAs. The kits come ready to use eliminating any plate coating or blocking as well as eliminates lengthy sample incubations. The assays can be completed in under 3 hours using only 100 uL of sample. Performance characteristics such as precision CVs less than 10%, recovery and linearity averaging at 82% and 102% respectively, and cross-reactivity with other collagen types of less than 0.004% provide reliable, accurate and sensitive assays for the detection mouse Collagen Type II antibodies.

 

The addition of these assays enhances the arthritis products and services currently offered by MD Biosciences. Research products include assays for measuring type II collagen and antibodies, assay for staining type II collagen, induction reagents such as collagen, adjuvant and ArthritoMabÒ antibody cocktail. Pre-clinical services include collagen-induced arthritis (CIA), Antibody induced arthritis (CAIA), Adjuvant Induced Arthritis as well as in vitro disease models providing the researcher a well-rounded approach for using MD Biosciences products in-house as well as outsourcing other areas of their drug discovery platform.

 

 

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 


The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

 

 

Read More

Topics: Research Products

MD Biosciences Releases Mouse OVA-IgE ELISA

Posted by Amy Clausen on Aug 3, 2007 11:30:00 AM

MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new Mouse OVA-IgE ELISA. The OVA-IgE ELISA offers researchers sensitive, reproducible, accurate and reliable results for the measurement of OVA specific IgE in mouse serum and cell culture supernate samples. The kit is ready-to-use with all necessary reagents and can be completed in under 2.5 hours, requires small sample sizes and measures levels down to 7.8 ng/mL with a sensitivity of less than 3.8 ng/mL.

Ovalbumin is widely used in inducing an allergic response in mouse models of allergic asthma. Through T cell and B cell signalling, IgE production is stimulated and released into the bloodstream where IgE attaches to cells such as mast cells and basophils. These cells are then activated after the IgE is cross-linked with antigen, initiating the allergic cascade.

In addition the Mouse OVA-IgE ELISA, MD Biosciences also offers other reagents such as T1/ST2 antibodies, in vitro assay services and efficacy disease models for the study of allergic asthma.

About MD Biosciences

MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

###

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Research Products

High ArthritoMabTM Antibody Cocktail Activity |18-day RA Model Balb/c Mice

Posted by Amy Clausen on Apr 3, 2007 11:33:00 AM

MD Biosciences releases histology results from an 18-day model of arthritis induced using the ArthritoMab(TM) cocktail of arthritogenic antibodies in Balb/c mice. Results show significant histological changes in the joint of the arthritis group as compared to the normal control group after just 18 days, providing researchers valuable data quickly compared to the traditional collagen-induced arthritis (CIA) model, which can take several weeks or more to produce similar histological results.

Results show significant histological changes in the joint of the arthritis group as compared to the normal control group after just 18 days, providing researchers valuable data quickly compared to the traditional collagen-induced arthritis (CIA) model, which can take several weeks or more to produce similar histological results. Figures 1-3 show the effectiveness of the arthritogenic antibodies, with mean histology scores and staining sections indicating the degree of erosion, hyperplasia and infiltration in the joint of the arthritis group as compared to the control group.

 

ArthritoMab histology

 

 

The ArthritoMabTM Arthritogenic Antibody Cocktail is comprised of 4 monoclonal antibodies to collagen type II (CII) that have been chosen for their epitope specificity. An antibody response to certain epitopes is better associated with arthritis than a response to other epitopes. In the CIA model, the antibody response correlated with arthritis was mainly associated with binding to the epitopes C1, J1, and U1. The ArthritoMabTM monoclonal antibodies were selected to bind to the epitopes C1, J1, U1 and D3 - which are spread over the entire CII region (fragments CB8, CB10 and CB11) encouraging better immune complex formation on the cartilage surface for the initiation of arthritis. The antibody-induced arthritis model using the ArthritoMabTM Arthritogenic Antibody cocktail is a rapid alternative the CIA model.

About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.

 

###

 

The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.

Read More

Topics: Inflammation, Research Products

MD Biosciences Releases New - Improved Collagen Type II ELISA

Posted by Amy Clausen on Feb 28, 2007 11:36:00 AM


St Paul, MN, January 9, 2007 - MD Biosciences, a global biotechnology company focused in inflammations research, accounces the launch of its new and improved Collagen Type II (CII) ELISA for the study of collagen metabolism. CII is a triple stranded pro-molecule that is found predomiinantly, but not exclusively, in cartilage. It's promary role is to provide cartilage with tensile strength and elasticity. Autoimmunity to CII is thought to play a role in the pathogenesis of many autoimmune diseases such as rheumatoid arthritis.

This ELISA offers many improvements over other commercially available CII ELISAs such as increased sensitivity, reproducibility, and accuracy for the reliability of results. The ELISA is designed to quantify the amount of collagen type II produced by cells or present in tissue across a variety of species. The ELISA is also highly specific to CII offering no cross-reactivity to other types of collagen providing reliable results.

In addition to performance improvements, user-friendly improvements such as pre-coated microplates and ready-to-use reagents increase the usability and decrease the preparation time allowing researchers to obtain rapid results in less than 5 hours.

About MD Biosciences
MD Biosciences provides products and pre-clinical services to companies engaged in inflammation and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to provide flexible drug discovery solutions, enabling smarter results faster.

 

Read More

Topics: Research Products